Kura Oncology (KUR) Price & Analysis

8 Followers

KUR Stock Chart & Stats

€8.88

-€0.86(-9.68%)

At close: Jul 29 4:00 PM EDT

€8.88

-€0.86(-9.68%)

Day’s Range― - ―

52-Week Range€6.15 - €10.80

Previous CloseN/A

Volume0.00

Average Volume (3M)26.00

Market Cap

€945.25M

Enterprise Value€480.17

Total Cash (Recent Filing)€519.02M

Total Debt (Recent Filing)€24.45M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Oct 29, 2026

EPS Estimate

-0.7

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.37

Shares Outstanding88,960,620

10 Day Avg. Volume0

30 Day Avg. Volume26

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)5.23

Price to Sales (P/S)13.50

P/FCF Ratio-12.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€24.14

Price Target Upside171.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-2.78

Revenue Forecast (FY)€84.23M

Bulls Say, Bears Say

Bulls Say

Early Commercial AdoptionCOMZIFTI has established an initial commercial foothold in NPM1-mutant AML. Growing starts and prescriptions, combined with majority new-start share, indicate product adoption that could support a durable revenue base as market penetration expands.

Clinical DifferentiationStrong response data across the KOMET program support ziftomenib’s potential clinical differentiation in genetically defined AML. Durable efficacy could improve prescribing, expand eligible use, and strengthen the commercial value of the lead product.

Funding And Partnership SupportKyowa Kirin support and projected collaboration revenue provide meaningful funding visibility for the lead AML program. This reduces immediate financing pressure and gives Kura time to reach pivotal clinical milestones without relying solely on new equity.

Bears Say

Persistent Operating LossesKura remains structurally unprofitable despite emerging product revenue and strong gross margins. Large operating losses require continued external funding and make eventual profitability dependent on successful commercialization and substantial revenue growth.

Cash Burn And Balance Sheet PressureNegative cash generation and a sizeable decline in liquidity show that development and commercial investment are consuming resources. If burn persists or milestones are delayed, Kura may need additional funding, creating dilution and financial flexibility risk.

Long-Dated Clinical Execution RiskMajor value-creating clinical readouts remain years away, leaving substantial uncertainty around trial execution, timing, efficacy durability, and real-world outcomes. Delays or weaker results could postpone broader adoption and extend the company’s funding needs.

Kura Oncology News

Morning Movers: Dick’s Sporting plummets following Q2 results, guidance cut

Stock futures are pointing to a stronger open as technology stocks rebound from Monday’s selloff. The bond market...

20h ago

AMD

Closing Bell Movers: Gorilla Technology falls 9% after results

Fragile sentiment in the tech space weighed on broader indices as S&P 500 and Nasdaq Composite begin the...

1d ago

Kura Oncology CEO buys $1.24M in common stock

In a regulatory filing, Kura Oncology (KURA) disclosed that its CEO Troy Wilson bought 100K shares of common...

1d ago

KURA

Closing Bell Movers: Fabrinet down 7% after results

S&P 500 index retreated for the second consecutive trading session on Monday and has now erased gains made...

8d ago

Kura Oncology CEO buys $1.11M in common stock

In a regulatory filing, Kura Oncology (KURA) disclosed that its CEO Troy Wilson bought 100K shares of common...

9d ago

KURA

Kura Oncology reports Q2 EPS (77c), consensus (88c)

Reports Q2 revenue $20.87M, consensus $20.18M. “In only its second full quarter of launch, KOMZIFTI established early leadership...

9d ago

KURA

Kura Oncology price target raised to $31 from $30 at BofA

BofA raised the firm’s price target on Kura Oncology (KURA) to $31 from $30 and keeps a Buy...

9d ago

KURA

Kura Oncology announces publication in Blood on ziftomenib binding profile

Kura Oncology (KURA) announced the publication of a manuscript in Blood, the flagship journal of the American Society...

16d ago

KURA

Kura Oncology announces durable activity of darlifarnib combination in ccRCC

Kura Oncology (KURA) announced updated Phase 1a results from the ongoing FIT-001 clinical trial demonstrating encouraging and durable...

30d ago

KURA

Kura Oncology Earnings Call Highlights COMZIFTI Momentum

Kura Oncology (($KURA)) has held its Q2 earnings call. Read on for the main highlights of the call....

2d ago

KURA

Phil Nadeau Reiterates Buy on Kura Oncology as Komzifti Outperforms Expectations and Pipeline Progress Strengthens Long-Term Outlook

TD Cowen analyst Phil Nadeau has maintained their bullish stance on KURA stock, giving a Buy rating today....

13d ago

KURA

Kura Oncology: Buy Rating Reiterated on Strong KOMZIFTI Momentum, Solid Cash Runway, and Unchanged $40 Price Target

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kura Oncology, with...

13d ago

KURA

KURA Earnings this Week: How Will it Perform?

Kura Oncology (KURA) is scheduled to report 2nd quarter earnings on 08/12/2026, after the market closes. Regarding Q2...

16d ago

KURA

Kura Oncology Enhances Executive Severance, Change-in-Control Terms

Kura Oncology ( ($KURA) ) has shared an announcement. On July 24 and July 27, 2026, Kura Oncology,...

27d ago

KURA

KUR FAQ

What was Kura Oncology’s price range in the past 12 months?

Kura Oncology lowest stock price was €6.15 and its highest was €10.80 in the past 12 months.

What is Kura Oncology’s market cap?

Kura Oncology’s market cap is €945.25M.

When is Kura Oncology’s upcoming earnings report date?

Kura Oncology’s upcoming earnings report date is Oct 29, 2026 which is in 64 days.

How were Kura Oncology’s earnings last quarter?

Kura Oncology released its earnings results on Aug 12, 2026. The company reported -€0.659 earnings per share for the quarter, beating the consensus estimate of -€0.751 by €0.092.

Is Kura Oncology overvalued?

According to Wall Street analysts Kura Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kura Oncology pay dividends?

Kura Oncology does not currently pay dividends.

What is Kura Oncology’s EPS estimate?

Kura Oncology’s EPS estimate is -0.7.

How many shares outstanding does Kura Oncology have?

Kura Oncology has 88,960,620 shares outstanding.

What happened to Kura Oncology’s price movement after its last earnings report?

Kura Oncology reported an EPS of -€0.659 in its last earnings report, beating expectations of -€0.751. Following the earnings report the stock price went up 1.182%.

Which hedge fund is a major shareholder of Kura Oncology?

Currently, no hedge funds are holding shares in DE:KUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kura Oncology Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-13.87%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Kura Oncology (KUR) Earnings & Revenues

Historic Earnings Reports

KUR Company Deck

KUR Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong early commercial traction for COMZIFTI (notable revenue, majority share of new patient starts, high Q/Q growth in starts and prescriptions), robust clinical data across Ziftomenib and promising darlifarnib combination signals in multiple solid tumor settings. Financials show solid funding runway with Kyowa Kirin support but also reflect increased commercial spend, a declining cash balance since year‑end, and a YoY decline in collaboration revenue. Competitive noise around market share and the multi‑year timelines to pivotal readouts add uncertainty. Overall, positive operational and clinical momentum is balanced against near‑term financial and competitive considerations.View all DE:KUR earnings summaries

KUR Stock 12 Month Forecast

Average Price Target

€24.14

▲(171.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","35":"€35","11.75":"€11.75","19.5":"€19.5","27.25":"€27.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34.2161088,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€34.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.14136565333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.8310408,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.83</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,11.75,19.5,27.25,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.02,10.035085292307691,12.050170584615383,14.065255876923077,16.08034116923077,18.09542646153846,20.110511753846154,22.125597046153846,24.140682338461538,26.15576763076923,28.17085292307692,30.185938215384613,32.20102350769231,{"y":34.2161088,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.02,9.26010505025641,10.50021010051282,11.74031515076923,12.980420201025641,14.220525251282051,15.46063030153846,16.70073535179487,17.94084040205128,19.18094545230769,20.4210505025641,21.66115555282051,22.90126060307692,{"y":24.14136565333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.02,8.39008006153846,8.760160123076922,9.130240184615385,9.500320246153846,9.870400307692307,10.240480369230768,10.61056043076923,10.980640492307693,11.350720553846154,11.720800615384615,12.090880676923078,12.460960738461537,{"y":12.8310408,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.176,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.788,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.966,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.612,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.252,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.92,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.78,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >